Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery (PHOENICS)

January 30, 2024 updated by: Fresenius Kabi

Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery

The aim of the study is to investigate the safety of a 6% HES (Hydroxyethyl Starch) solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in patients undergoing elective abdominal surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

2289

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Sankt Veit, Austria
        • General Hospital of Barmherzige Brüder
      • Vienna, Austria
        • Social Medical Center East - Donauspital
  • Belgium
      • Brussels, Belgium
        • Cliniques Universitaires Saint Luc
      • Gent, Belgium
        • AZ Maria Middelares
      • Hasselt, Belgium
        • Jessa Ziekenhuis
  • Croatia
      • Zagreb, Croatia
        • University Hospital Zagreb
      • Zagreb, Croatia
        • University Hospital Sisters of Mercy
      • Zagreb, Croatia
        • Clinical Hospital Sveti Duh
  • Czechia
      • Kolín, Czechia
        • Kolín Hospital
      • Prague, Czechia
        • General University Hospital in Prague
      • Prague, Czechia
        • University Hospital Motol
      • Prague, Czechia
        • Central Military Hospital Prague
  • France
      • Angers, France
        • Chu Angers
      • Bourgoin-Jallieu, France
        • Hospital Centre Pierre Oudot
      • Lille, France
        • CHRU Lille
      • Montauban, France
        • Hospital Centre Montauban
      • Montpellier, France
        • Montpellier University Hospital
      • Paris, France
        • Hôpital Europeen Georges Pompidou
      • Paris, France
        • AP-HP Paris (Salpêtrière)
      • Paris, France
        • Hospital Saint-Antoine
      • Strasbourg, France
        • University Hospital of Strasbourg
      • Suresnes, France
        • Hospital Foch Suresnes
      • Valenciennes, France
        • Hospital Jean Bernard
  • Germany
      • Cottbus, Germany
        • Carl-Thiem-Klinikum
      • Dachau, Germany
        • Helios Amper-Klinikum
      • Dresden, Germany
        • Universitatsklinikum Carl Gustav Carus
      • Kiel, Germany
        • University Hospital Schleswig-Holstein Campus Kiel
      • Köln, Germany
        • Kliniken der Stadt Köln
      • Marburg, Germany
        • University Hospital Marburg
      • München, Germany
        • University Hospital Munich
      • Münster, Germany
        • Universitätsklinikum Münster
      • Oldenburg, Germany
        • Klinikum Oldenburg AöR
      • Pinneberg, Germany
        • Regio Klinikum Pinneberg GmbH
  • Netherlands
      • Amsterdam, Netherlands
        • Amsterdam Medical Centre
      • Groningen, Netherlands
        • University Medical Center Groningen
      • Groningen, Netherlands
        • Martini General Hospital Groningen
      • Maastricht, Netherlands
        • University Medical Center (UMC) Maastricht
  • Poland
      • Gdańsk, Poland
        • University Clinical Center Gdansk
      • Katowice, Poland
        • Medical University of Silesia
      • Konin, Poland
        • Wojewodzki Szpital Zespolony
      • Końskie, Poland
        • Szpital Specjalistyczny im. Św. Łukasza
      • Kraków, Poland
        • Jagiollonian University Hospital Medical College
      • Lublin, Poland
        • Medical University of Lublin
      • Poznań, Poland
        • Karol Marcinkowski Medical University in Poznań
      • Wrocław, Poland
        • University Hospital in Wroclaw
      • Zielona Góra, Poland
        • Klinika Wiśniowa
  • Romania
      • Bucharest, Romania
        • Fundeni Clinical Institute 1
      • Bucharest, Romania
        • Fundeni Clinical Institute 2
      • Bucharest, Romania
        • University Hospital Elias Bucharest
      • Cluj-Napoca, Romania
        • Emergency county hospital Cluj
  • Spain
      • Barcelona, Spain
        • Hospital Santa Creu i Sant Pau
      • Barcelona, Spain
        • Barcelona Clinic Hospital
      • Elche, Spain
        • University Hospital General Del Elche
      • Las Palmas de Gran Canaria, Spain
        • Hospital Universitario de Gran Canaria Dr. Negrin
      • Madrid, Spain
        • Hospital Ramon y Cajal
      • Madrid, Spain
        • Hospital Gregorio Maranon
      • Madrid, Spain
        • Hospital Universitario Fundacion Alcorcon
      • Málaga, Spain
        • Quironsalud
      • Valencia, Spain
        • Hospital Universitari i Politecnic La Fe
      • Valencia, Spain
        • Hospital Clínico Universitario Valencia
      • Valladolid, Spain
        • Hospital Universitario Rio Hortega

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

41 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion:

  • Male or female adult patients > 40 and ≤ 85 years of age. Women of child bearing potential must test negative on standard pregnancy test (urine or serum)
  • Patients undergoing elective abdominal surgery with an expected blood loss of ≥ 500 ml
  • ASA Physical Status II - III
  • Signed written informed consent form

Exclusion:

  • Hypersensitivity to the active substances or to any of the other excipients of the investigational medicinal products
  • Body weight ≥ 140 kg
  • Sepsis
  • Burns
  • Renal impairment (AKIN stage ≥ 1 or chronic) or acute and/or chronic renal replacement therapy
  • Intracranial or cerebral haemorrhage
  • Critically ill patients (typically admitted to the intensive care unit)
  • Hyperhydration
  • Pulmonary oedema
  • Dehydration
  • Hyperkalaemia
  • Severe hypernatraemia
  • Severe hyperchloraemia
  • Severely impaired hepatic function
  • Congestive heart failure
  • Severe coagulopathy
  • Organ transplant patients
  • Metabolic alkalosis
  • Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Volulyte 6%
Volulyte 6% solution for infusion
Drug: Volulyte 6%
Solution for infusion
Other Names:
  • Hydroxyethyl starch 130/0.4
Active Comparator: Ionolyte
Ionolyte solution for infusion
Drug: Ionolyte
Solution for infusion
Other Names:
  • Electrolyte solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Difference in mean estimated glomerular filtration rate (eGFR) (calculated from highest cystatin-C levels measured during post-operative days 1-3 (POD 1-3)) between the two treatment groups
Time Frame: post-operative days 1-3
post-operative days 1-3

Secondary Outcome Measures

Outcome Measure
Time Frame
Mortality
Time Frame: 1 year
1 year
Renal function
Time Frame: until 1 year after surgery
until 1 year after surgery
Calculated red blood cell (RBC) loss
Time Frame: on post-operative day 3
on post-operative day 3
Estimated intra-operative blood loss
Time Frame: end of surgery
end of surgery
Coagulation
Time Frame: until post-operative day 1
until post-operative day 1
Inflammation
Time Frame: until post-operative day 1
until post-operative day 1
Adverse events
Time Frame: until post-operative day 90
until post-operative day 90
Major post-operative complications
Time Frame: until post-operative day 90
until post-operative day 90
Composite of mortality and major post-operative complications (including renal)
Time Frame: until post-operative day 90
until post-operative day 90
Total volume of administered investigational product
Time Frame: until 24 hours after investigational product treatment start
until 24 hours after investigational product treatment start
Fluid balance [Sum of volume of all intravenous medication (including investigational product and blood products) minus sum of volume of urine output (if available), drainage and estimated intra-operative blood loss]
Time Frame: until post-operative day 3
until post-operative day 3
Heart Rate
Time Frame: until post-operative day 3
until post-operative day 3
Body temperature
Time Frame: until post-operative day 3
until post-operative day 3
Mean arterial pressure
Time Frame: until post-operative day 3, if available
until post-operative day 3, if available
Systolic arterial blood pressure
Time Frame: until end of surgery
until end of surgery
Diastolic arterial blood pressure
Time Frame: until end of surgery
until end of surgery
Central venous pressure (if available)
Time Frame: until end of surgery
until end of surgery
Haemodynamics readings as required to determine volume responsiveness [at least one parameter (stroke volume, stroke volume variation, stroke volume index, pulse pressure variation, mean arterial pressure) has to be used to guide volume administration]
Time Frame: until 24 hours after investigational product treatment start
until 24 hours after investigational product treatment start
Partial pressure of carbon dioxide
Time Frame: until end of surgery
until end of surgery
Partial pressure of oxygen
Time Frame: until end of surgery
until end of surgery
Bicarbonate
Time Frame: until end of surgery
until end of surgery
Arterial oxygen saturation
Time Frame: until end of surgery
until end of surgery
Haemoglobin
Time Frame: until post-operative day 3
until post-operative day 3
Haematocrit
Time Frame: until post-operative day 3
until post-operative day 3
pH
Time Frame: until end of surgery
until end of surgery
Base Excess
Time Frame: until end of surgery
until end of surgery
Lactate
Time Frame: until post-operative day 3
until post-operative day 3
Central venous oxygen saturation (if available)
Time Frame: until post-operative day 1
until post-operative day 1
Serum sodium
Time Frame: until post-operative day 1
until post-operative day 1
Serum potassium
Time Frame: until post-operative day 1
until post-operative day 1
Serum calcium
Time Frame: until post-operative day 1
until post-operative day 1
Serum chloride
Time Frame: until post-operative day 1
until post-operative day 1
Length of stay in the hospital/intensive care unit
Time Frame: until post-operative day 90
until post-operative day 90
Hours on mechanical ventilation
Time Frame: until post-operative day 7
until post-operative day 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fresenius Kabi

Collaborators

B. Braun Melsungen AG
European Society of Anaesthesiology and Intensive Care

Investigators

  • Study Chair: Wolfgang F. Buhre, Prof. Dr. med., Department of Anesthesiology and Pain Management, Maastricht University, The Netherlands

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 28, 2017

Primary Completion (Actual)

April 9, 2022

Study Completion (Actual)

July 6, 2022

Study Registration Dates

First Submitted

September 8, 2017

First Submitted That Met QC Criteria

September 8, 2017

First Posted (Actual)

September 11, 2017

Study Record Updates

Last Update Posted (Estimated)

January 31, 2024

Last Update Submitted That Met QC Criteria

January 30, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HC-G-H-1504
  • HE06-024-CP4 (Other Identifier: Fresenius Kabi)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypovolaemia Due to Acute Blood Loss

Clinical Trials on Volulyte 6%

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe